Reading a semaglutide chart: what the dose progression and trial results really tell you

The biggest myth: a higher number on the chart means a better outcome

This is the misconception worth correcting first. When people look at a semaglutide dosing chart, they often read it like a ladder where the goal is simply to reach the top rung as fast as possible. That framing is wrong, and it can lead to real problems.

The titration steps (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) exist primarily to give your digestive system time to adjust. Gastrointestinal side effects (nausea, vomiting, loose stools, reflux) are most common after a dose increase, and the slow schedule reduces their severity for most people. Rushing to the maintenance dose does not speed up weight loss in any linear way; it mainly raises the chance of side effects that then force a step back down.

What a prescriber looks for at each review is not "has the patient hit 2.4 mg" but "is this person tolerating the current dose, and is there clinical reason to increase it." The chart is a titration guide, not a finish line. If you are reading a semaglutide dosing chart for weight loss and using it to plan your own schedule, that is a sign the process needs a qualified prescriber behind it. The NHS guidance on semaglutide as a medicine is clear that dose changes should follow clinical assessment, not a timeline.

The same caution applies to the 7.2 mg tier now available. That dose was approved by the MHRA on 14 April 2026 as a dedicated single-dose pen, and if you want to understand how the units translate across pens and doses, our semaglutide units chart breaks down the numbers clearly so nothing gets misread at the point of administration.

What the weight-loss results chart actually measured (and what it didn't

Results charts for semaglutide circulate widely online, and the headline figure) roughly 15% average body-weight reduction over 68 weeks, comes from the STEP 1 trial, published in the New England Journal of Medicine. That trial enrolled adults with obesity or overweight plus a weight-related condition, without type 2 diabetes. Participants also followed a reduced-calorie diet and increased their activity levels alongside the medicine.

Three things often get lost when that chart is reproduced on social media or forums. First, 15% is a mean: some people in the trial lost considerably more, others less. Second, the curve on the chart reaches its lowest point around weeks 60–68 and then tends to plateau, the medicine does not keep producing the same rate of loss indefinitely at the same dose. Third, the trial excluded people with a history of pancreatitis, certain thyroid conditions and other contraindications; the chart represents a specific, assessed population, not everyone who might want to try semaglutide.

For a fuller picture of how those figures compare across doses and medicines, the Wegovy results chart page works through the data in more detail, including what the 7.2 mg trial arm adds to the picture.

Where the semaglutide half-life fits into the chart

A question that comes up often (and shapes how the dosing chart is structured) is why semaglutide is taken once a week rather than daily. The answer is its half-life: semaglutide remains active in the body for approximately a week, which is why once-weekly dosing maintains a relatively stable plasma level between injections.

This matters for reading charts because it means blood concentration does not spike and crash the way a shorter-acting medicine might. The plateau visible on longer-term results charts partly reflects this steady-state pharmacokinetics. If you have seen a semaglutide half-life chart plotting concentration over days, the gently rolling wave it shows (rather than sharp peaks and troughs) explains why the clinical effects feel gradual rather than day-by-day variable.

It also explains the washout logic when stopping: because semaglutide stays in the system for several weeks after the last dose, appetite does not return immediately when treatment ends. Any decisions around stopping, pausing or switching are ones to make with a prescriber. Our clinical team at nume is made up of GPhC-registered Independent Prescribers who review every case personally.

How Wegovy's licensed place in the UK shapes the chart you're looking at

Not every semaglutide chart you find online reflects UK licensing. Some originate from the US (where Wegovy has been available longer), some predate the 7.2 mg approval, and some conflate Wegovy with Ozempic, which is also semaglutide, but licensed for type 2 diabetes, not weight management.

In the UK, Wegovy is the licensed brand for weight management. NICE recommends it under Technology Appraisal 875 within specialist weight management services, for up to two years, with specific BMI and comorbidity thresholds. Private prescribing follows the licensed eligibility criteria set out in the Wegovy SmPC. If a chart you have seen quotes different doses or strengths (3 mg, 7 mg, 14 mg) those are Rybelsus (oral semaglutide for diabetes), not Wegovy's weight-loss tablet schedule.

The oral Wegovy tablet, approved by the MHRA on 11 June 2026, has its own chart: it titrates from 1.5 mg daily up to a 25 mg maintenance dose over several months, and people wondering how the upper end of that schedule compares to the injectable programme may find it useful to read about step 9 semaglutide, which covers what reaching the highest titration point involves in practice. That is a different device, a different formulation and a different titration entirely, worth checking the right chart before drawing conclusions.

If you are trying to work out where you might sit on any of these charts, the starting point is a clinical consultation. For context on what treatment costs privately in the UK, our weight-loss treatments page sets out what is included in one transparent price. When you feel ready to talk through your options, you are welcome to speak to our prescribers.